Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Re-arrangements of gene transcripts at glutamatergic synapses after prolonged treatments with antipsychotics: A putative link with synaptic remodeling.
Buonaguro EF, Iasevoli F, Marmo F, Eramo A, Latte G, Avagliano C, Tomasetti C, de Bartolomeis A. Buonaguro EF, et al. Among authors: avagliano c. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 2;76:29-41. doi: 10.1016/j.pnpbp.2017.02.012. Epub 2017 Feb 22. Prog Neuropsychopharmacol Biol Psychiatry. 2017. PMID: 28235555
Glutamatergic postsynaptic density in early life stress programming: Topographic gene expression of mGlu5 receptors and Homer proteins.
Buonaguro EF, Morley-Fletcher S, Avagliano C, Vellucci L, Iasevoli F, Bouwalerh H, Van Camp G, Nicoletti F, Maccari S, de Bartolomeis A. Buonaguro EF, et al. Among authors: avagliano c. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jan 10;96:109725. doi: 10.1016/j.pnpbp.2019.109725. Epub 2019 Aug 9. Prog Neuropsychopharmacol Biol Psychiatry. 2020. PMID: 31404590
Translating preclinical findings in clinically relevant new antipsychotic targets: focus on the glutamatergic postsynaptic density. Implications for treatment resistant schizophrenia.
de Bartolomeis A, Avagliano C, Vellucci L, D'Ambrosio L, Manchia M, D'Urso G, Buonaguro EF, Iasevoli F. de Bartolomeis A, et al. Among authors: avagliano c. Neurosci Biobehav Rev. 2019 Dec;107:795-827. doi: 10.1016/j.neubiorev.2019.08.019. Epub 2019 Aug 25. Neurosci Biobehav Rev. 2019. PMID: 31461641 Review.
Modulation of glutamatergic functional connectivity by a prototypical antipsychotic: Translational inference from a postsynaptic density immediate-early gene-based network analysis.
Barone A, Signoriello S, Latte G, Vellucci L, Giordano G, Avagliano C, Buonaguro EF, Marmo F, Tomasetti C, Iasevoli F, de Bartolomeis A. Barone A, et al. Among authors: avagliano c. Behav Brain Res. 2021 Apr 23;404:113160. doi: 10.1016/j.bbr.2021.113160. Epub 2021 Feb 9. Behav Brain Res. 2021. PMID: 33577880
Disorganization domain as a putative predictor of Treatment Resistant Schizophrenia (TRS) diagnosis: A machine learning approach.
Barone A, De Prisco M, Altavilla B, Avagliano C, Balletta R, Buonaguro EF, Ciccarelli M, D'Ambrosio L, Giordano S, Latte G, Matrone M, Milandri F, Francesco DN, Vellucci L, de Bartolomeis A. Barone A, et al. Among authors: avagliano c. J Psychiatr Res. 2022 Nov;155:572-578. doi: 10.1016/j.jpsychires.2022.09.044. Epub 2022 Sep 29. J Psychiatr Res. 2022. PMID: 36206601
Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables.
de Bartolomeis A, Prinzivalli E, Callovini G, D'Ambrosio L, Altavilla B, Avagliano C, Iasevoli F. de Bartolomeis A, et al. Among authors: avagliano c. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 2;81:356-366. doi: 10.1016/j.pnpbp.2017.09.002. Epub 2017 Sep 5. Prog Neuropsychopharmacol Biol Psychiatry. 2018. PMID: 28887181 Clinical Trial.
Evaluation of a few discrete clinical markers may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: A study by ROC curve analysis and multivariate analyses.
Iasevoli F, Avagliano C, Altavilla B, Barone A, Ciccarelli M, D'Ambrosio L, Notar Francesco D, Razzino E, Fornaro M, de Bartolomeis A. Iasevoli F, et al. Among authors: avagliano c. Psychiatry Res. 2018 Nov;269:481-493. doi: 10.1016/j.psychres.2018.08.109. Epub 2018 Aug 31. Psychiatry Res. 2018. PMID: 30195742
Disease Severity in Treatment Resistant Schizophrenia Patients Is Mainly Affected by Negative Symptoms, Which Mediate the Effects of Cognitive Dysfunctions and Neurological Soft Signs.
Iasevoli F, Avagliano C, Altavilla B, Barone A, D'Ambrosio L, Matrone M, Notar Francesco D, Razzino E, de Bartolomeis A. Iasevoli F, et al. Among authors: avagliano c. Front Psychiatry. 2018 Oct 31;9:553. doi: 10.3389/fpsyt.2018.00553. eCollection 2018. Front Psychiatry. 2018. PMID: 30429802 Free PMC article.
Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia.
Iasevoli F, Razzino E, Altavilla B, Avagliano C, Barone A, Ciccarelli M, D'Ambrosio L, Matrone M, Milandri F, Notar Francesco D, Fornaro M, de Bartolomeis A. Iasevoli F, et al. Among authors: avagliano c. Early Interv Psychiatry. 2022 Apr;16(4):352-362. doi: 10.1111/eip.13174. Epub 2021 May 16. Early Interv Psychiatry. 2022. PMID: 33998142 Free PMC article. Clinical Trial.
43 results